Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 1-Year High – What’s Next?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $135.16 and last traded at $133.98, with a volume of 309350 shares changing hands. The stock had previously closed at $129.98.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research reports. TD Cowen decreased their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Stock Performance

The company has a market capitalization of $8.11 billion, a price-to-earnings ratio of 18.92, a P/E/G ratio of 0.92 and a beta of 0.56. The firm’s 50 day simple moving average is $122.56 and its 200-day simple moving average is $116.63. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 5,053 shares of company stock valued at $617,442 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $25,000. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $28,000. Allianz SE acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Jones Financial Companies Lllp lifted its holdings in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 130 shares in the last quarter. Finally, UMB Bank n.a. grew its position in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares during the period. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.